Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Hemostemix Inc HMTXF

Primary Symbol: V.HEM

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Add To Watchlist

Recent & Breaking News (TSXV:HEM)

Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States

Marketwired December 22, 2015

Hemostemix Announces Closing of the First Tranche of Brokered Private Placement

Marketwired December 2, 2015

Hemostemix Invited to Prestigious JP Morgan Conference

Marketwired November 30, 2015

Hemostemix Amends Terms of Private Placement

Marketwired November 5, 2015

Hemostemix Names Jim Brown to Board of Directors

Marketwired October 26, 2015

Hemostemix Announces Brokered Private Placement

Marketwired October 8, 2015

Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa

Marketwired October 5, 2015

Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan

Marketwired September 14, 2015

Hemostemix Holds First Meeting of Data Safety Monitoring Board (DSMB)

Marketwired August 20, 2015

Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States

Marketwired August 10, 2015

Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia

Marketwired July 27, 2015

Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia

Marketwired July 27, 2015

Hemostemix Forms Strategic Alliance in Asia

Marketwired July 23, 2015

Hemostemix Posts Corporate Presentation on Company Website

Marketwired July 7, 2015

Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia

Marketwired June 25, 2015

Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company's ACP-01 Formulation to Treat Critical Limb Ischemia

Marketwired June 18, 2015

Hemostemix and Ludwig Boltzmann Institute for Experimental and Clinical Traumatology Enter Into Research Collaboration Agreement to Develop Hemostemix Regenerative Technology

Marketwired June 17, 2015

Hemostemix Names Dr. Rahul Sarugaser as Vice President of Business and Corporate Development

Marketwired June 16, 2015

Hemostemix to Present in Italy at the 2015 Gordon Research Conference on Assisted Circulation

Marketwired June 15, 2015

Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia (CLI)

Marketwired May 19, 2015